Cargando…

Anti-GBM Disease after Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccination: A Report of Two Cases

There have been reports of rare de novo glomerular diseases following vaccination for coronavirus disease 2019 (COVID-19). We report two cases of anti-glomerular basement membrane (GBM) disease in previously healthy females after Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19). The first case...

Descripción completa

Detalles Bibliográficos
Autores principales: Coorey, Craig Peter, Phua, Elaine, Chou, Angela, Shen, Yvonne, Mather, Amanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710461/
https://www.ncbi.nlm.nih.gov/pubmed/36465571
http://dx.doi.org/10.1159/000525737
_version_ 1784841372108324864
author Coorey, Craig Peter
Phua, Elaine
Chou, Angela
Shen, Yvonne
Mather, Amanda
author_facet Coorey, Craig Peter
Phua, Elaine
Chou, Angela
Shen, Yvonne
Mather, Amanda
author_sort Coorey, Craig Peter
collection PubMed
description There have been reports of rare de novo glomerular diseases following vaccination for coronavirus disease 2019 (COVID-19). We report two cases of anti-glomerular basement membrane (GBM) disease in previously healthy females after Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19). The first case was a 69-year-old female who developed lethargy and anuria approximately 8 weeks after her first dose of Oxford-AstraZeneca COVID-19 vaccine. The second case was a 72-year-old female who developed malaise and diarrhoea approximately 3 weeks after her second dose of Oxford-AstraZeneca COVID-19 vaccine. Both cases had severe acute kidney injury, raised anti-GBM antibody titres, and renal biopsies consistent with anti-GBM disease. Both cases were commenced on haemodialysis and treated with high dose glucocorticoids, cyclophosphamide, and plasmapheresis. Neither patient had recovery of renal function, and both remain dialysis dependent. These cases add to the previously reported cases of anti-GBM disease after mRNA COVID-19 vaccination. As more COVID-19 vaccinations are administered worldwide, it would be important for clinicians to be aware of this possible association, and continued surveillance is warranted.
format Online
Article
Text
id pubmed-9710461
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-97104612022-12-01 Anti-GBM Disease after Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccination: A Report of Two Cases Coorey, Craig Peter Phua, Elaine Chou, Angela Shen, Yvonne Mather, Amanda Case Rep Nephrol Dial Case Series There have been reports of rare de novo glomerular diseases following vaccination for coronavirus disease 2019 (COVID-19). We report two cases of anti-glomerular basement membrane (GBM) disease in previously healthy females after Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19). The first case was a 69-year-old female who developed lethargy and anuria approximately 8 weeks after her first dose of Oxford-AstraZeneca COVID-19 vaccine. The second case was a 72-year-old female who developed malaise and diarrhoea approximately 3 weeks after her second dose of Oxford-AstraZeneca COVID-19 vaccine. Both cases had severe acute kidney injury, raised anti-GBM antibody titres, and renal biopsies consistent with anti-GBM disease. Both cases were commenced on haemodialysis and treated with high dose glucocorticoids, cyclophosphamide, and plasmapheresis. Neither patient had recovery of renal function, and both remain dialysis dependent. These cases add to the previously reported cases of anti-GBM disease after mRNA COVID-19 vaccination. As more COVID-19 vaccinations are administered worldwide, it would be important for clinicians to be aware of this possible association, and continued surveillance is warranted. S. Karger AG 2022-11-22 /pmc/articles/PMC9710461/ /pubmed/36465571 http://dx.doi.org/10.1159/000525737 Text en Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Series
Coorey, Craig Peter
Phua, Elaine
Chou, Angela
Shen, Yvonne
Mather, Amanda
Anti-GBM Disease after Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccination: A Report of Two Cases
title Anti-GBM Disease after Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccination: A Report of Two Cases
title_full Anti-GBM Disease after Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccination: A Report of Two Cases
title_fullStr Anti-GBM Disease after Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccination: A Report of Two Cases
title_full_unstemmed Anti-GBM Disease after Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccination: A Report of Two Cases
title_short Anti-GBM Disease after Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccination: A Report of Two Cases
title_sort anti-gbm disease after oxford-astrazeneca chadox1 ncov-19 vaccination: a report of two cases
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710461/
https://www.ncbi.nlm.nih.gov/pubmed/36465571
http://dx.doi.org/10.1159/000525737
work_keys_str_mv AT cooreycraigpeter antigbmdiseaseafteroxfordastrazenecachadox1ncov19vaccinationareportoftwocases
AT phuaelaine antigbmdiseaseafteroxfordastrazenecachadox1ncov19vaccinationareportoftwocases
AT chouangela antigbmdiseaseafteroxfordastrazenecachadox1ncov19vaccinationareportoftwocases
AT shenyvonne antigbmdiseaseafteroxfordastrazenecachadox1ncov19vaccinationareportoftwocases
AT matheramanda antigbmdiseaseafteroxfordastrazenecachadox1ncov19vaccinationareportoftwocases